Methylation-induced transcriptional FGFR2 downregulation is thus associated with poorer prognosis in hepatocellular carcinoma [147] and bladder cancer [131], analogous to functional losses caused by FGFR2 deletion in glioblastomas [148], or loss of FGFR2 heterozygosity in osteosarcomas [149]. This evidence concerns the gene FGFR2 and glioblastoma.